GlassScriptPhysician profile
Anthony M Reginato
NPI 1134195043
$109,196.77
in general payments reported to CMS, 2019-2025
10 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $22K · 2021: $11K · 2022: $8,503 · 2023: $535 · 2024: $386 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218 · Consulting Fee: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,217.55 |
| Consulting Fee | $1,012.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $73,414.28 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $14,754.86 | 2019-2021 | |
| Eli Lilly and Company | $12,481.38 | 2019 | |
| Horizon Therapeutics Plc | $5,578.34 | 2019-2023 | Krystexxa |
| Abbvie INC. | $1,187.91 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $674.85 | 2019-2025 | |
| Janssen Biotech, INC. | $610.28 | 2022-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $277.64 | 2023-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $117.23 | 2022 | |
| Genentech USA, INC. | $100.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Reginato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.